Business Context and Reporting Period
This Form 8-K was filed by Manhattan Pharmaceuticals, Inc. on February 4, 2009, reporting events occurring on February 3, 2009. The filing details the final closing of a Securities Purchase Agreement originally entered into on November 19, 2008. Note: The request metadata references "TG THERAPEUTICS, INC.," but the filing text explicitly identifies the registrant as Manhattan Pharmaceuticals, Inc.
Key Financial Metrics and Transaction Details
The filing reports the sale of unregistered equity securities and debt instruments under a multi-stage closing process:
- Transaction Structure: Sale of "Units," each consisting of a 12% Senior Secured Note Promissory Note ($5,000 principal) and a warrant to purchase 166,667 shares of common stock at $0.09 per share (expiring December 31, 2013).
- Final Closing (Feb 3, 2009): Sale of 82 additional Units.
- Second Closing (Dec 23, 2008): Sale of 56 additional Units.
- Initial Closing (Nov 2008): Sale of 207 Units.
- Total Units Sold: 345 Units (207 + 56 + 82).
- Total Debt Principal Raised: $1,725,000 (345 Units x $5,000).
- Placement Agent Compensation: Issuance of a warrant to purchase 2,050,004 shares of common stock at $0.09 per share.
The filing does not provide specific revenue, profit, cash flow, or liquidity metrics for the reporting period.
Material Changes
The primary material change is the completion of the final tranche of the capital raise, increasing the company's debt load by $410,000 (82 Units x $5,000) and increasing potential equity dilution through the issuance of warrants for 13,666,694 shares (82 Units x 166,667 shares) plus the placement agent warrant.
Guidance, Risks, and Contingencies
The filing contains standard forward-looking statements regarding future events and expectations, noting that actual results may differ materially due to risk factors outlined in the Company's 2007 Form 10-K. No specific financial guidance or outlook is provided in this document. The securities issued are non-transferable without an effective registration statement or exemption.
Investor Verification Checklist
- Verify the total outstanding principal amount of the 12% Senior Secured Notes following the final closing.
- Confirm the total number of warrants outstanding and the potential dilution impact on existing shareholders.
- Review the Company's 2007 Form 10-K for specific risk factors referenced in the forward-looking statements.
- Check for any subsequent filings regarding the use of proceeds from the $1.725 million raised.